About Radiopharm Theranostics

Radiopharm Theranostics is a clinical-stage biotechnology company developing first-in-class radiopharmaceuticals for oncology targets. The company utilizes proprietary platforms including nanobodies, antibodies, small molecules, and peptides for precision targeting in radiotherapeutics and radiodiagnostics. Their focus is on advancing novel agents to address significant unmet needs in cancer care.

<problem> The development of effective cancer therapies is hindered by the need for targeted delivery mechanisms that can precisely reach tumor cells while minimizing off-target effects. Traditional treatments often lack the specificity required to address the complex heterogeneity of cancer, leading to suboptimal therapeutic outcomes and increased toxicity. </problem> <solution> Radiopharm Theranostics is a clinical-stage biotechnology company focused on developing first-in-class radiopharmaceuticals for oncology. The company leverages proprietary platforms, including nanobodies, antibodies, small molecules, and peptides, to create targeted therapies and diagnostics. By focusing on novel oncology pathways and avoiding commonly targeted antigens, Radiopharm aims to address significant unmet needs in cancer care. Their approach integrates advanced molecular targeting with radioisotope delivery to enhance therapeutic efficacy and diagnostic precision. </solution> <features> - Development of radiopharmaceutical candidates utilizing nanobody, antibody, small molecule, and peptide targeting modalities. - Focus on novel oncology targets, specifically excluding commonly targeted antigens such as PSMA, FAP, and SSTR2. - Pipeline includes therapeutic agents utilizing isotopes such as Lutetium-177 (Lu177) and Terbium-161 (Tb161). - Diagnostic imaging agents are being developed using isotopes like Fluorine-18 (F18) and Gallium-68 (Ga68). - Clinical-stage programs include Phase I and Phase II trials for various solid tumor indications. - Specific therapeutic programs target PD-L1 (RAD204), HER2 (RAD202), and B7-H3 (RV01/Betabart). - Diagnostic programs include FASN targeting for brain metastases (RAD101) and integrin αVβ6 targeting (RAD301). - Preclinical programs include KLK3 targeting for prostate cancer (RAD402) and integrin αVβ6 targeting for solid tumors (RAD302). - Strategic collaborations, including a joint venture with MD Anderson Cancer Center, support pipeline advancement. </features> <target_audience> The primary target audience includes oncologists, nuclear medicine physicians, and researchers involved in cancer therapy and diagnostics. </target_audience>

What does Radiopharm Theranostics do?

Where is Radiopharm Theranostics located?

Radiopharm Theranostics is based in Sydney, Australia.

When was Radiopharm Theranostics founded?

Radiopharm Theranostics was founded in 2021.

How much funding has Radiopharm Theranostics raised?

Radiopharm Theranostics has raised $5.0M.

Who founded Radiopharm Theranostics?

Radiopharm Theranostics was founded by Paul Hopper and Riccardo Canevari.

Paul Hopper - Founder
Riccardo Canevari - CEO

Location

Sydney, Australia

Founded

2021

Funding

$5.0M

Employees

21 employees

Major Investors

Lantheus Holdings

Radiopharm Theranostics

Sydney, AustraliaFounded 2021217K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 2 months ago

Funding

$5.0M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

The development of effective cancer therapies is hindered by the need for targeted delivery mechanisms that can precisely reach tumor cells while minimizing off-target effects. Traditional treatments often lack the specificity required to address the complex heterogeneity of cancer, leading to suboptimal therapeutic outcomes and increased toxicity.

Solution

Radiopharm Theranostics is a clinical-stage biotechnology company focused on developing first-in-class radiopharmaceuticals for oncology. The company leverages proprietary platforms, including nanobodies, antibodies, small molecules, and peptides, to create targeted therapies and diagnostics. By focusing on novel oncology pathways and avoiding commonly targeted antigens, Radiopharm aims to address significant unmet needs in cancer care. Their approach integrates advanced molecular targeting with radioisotope delivery to enhance therapeutic efficacy and diagnostic precision.

Target Audience

The primary target audience includes oncologists, nuclear medicine physicians, and researchers involved in cancer therapy and diagnostics.

Features

Development of radiopharmaceutical candidates utilizing nanobody, antibody, small molecule, and peptide targeting modalities.
Focus on novel oncology targets, specifically excluding commonly targeted antigens such as PSMA, FAP, and SSTR2.
Pipeline includes therapeutic agents utilizing isotopes such as Lutetium-177 (Lu177) and Terbium-161 (Tb161).
Diagnostic imaging agents are being developed using isotopes like Fluorine-18 (F18) and Gallium-68 (Ga68).
Clinical-stage programs include Phase I and Phase II trials for various solid tumor indications.
Specific therapeutic programs target PD-L1 (RAD204), HER2 (RAD202), and B7-H3 (RV01/Betabart).
Diagnostic programs include FASN targeting for brain metastases (RAD101) and integrin αVβ6 targeting (RAD301).
Preclinical programs include KLK3 targeting for prostate cancer (RAD402) and integrin αVβ6 targeting for solid tumors (RAD302).
Strategic collaborations, including a joint venture with MD Anderson Cancer Center, support pipeline advancement.